These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 33917696)

  • 1. Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs.
    Silva S; Almeida AJ; Vale N
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33917696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Role of Caffeine in the Treatment of Parkinson's Disease.
    Roshan MH; Tambo A; Pace NP
    Open Neurol J; 2016; 10():42-58. PubMed ID: 27563362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.
    Cummings JL; Henchcliffe C; Schaier S; Simuni T; Waxman A; Kemp P
    Brain; 2011 Nov; 134(Pt 11):3146-66. PubMed ID: 21810889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal treatment options for neurological disorders: impact on the elderly.
    Priano L; Gasco MR; Mauro A
    Drugs Aging; 2006; 23(5):357-75. PubMed ID: 16823990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of nuclear REST/NRSF in aged-dopaminergic neurons in Parkinson's disease patients.
    Kawamura M; Sato S; Matsumoto G; Fukuda T; Shiba-Fukushima K; Noda S; Takanashi M; Mori N; Hattori N
    Neurosci Lett; 2019 Apr; 699():59-63. PubMed ID: 30684677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanodelivery of therapeutic agents in Parkinson's disease.
    Lafuente JV; Requejo C; Ugedo L
    Prog Brain Res; 2019; 245():263-279. PubMed ID: 30961870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.
    Williams-Gray CH; Foltynie T; Lewis SJ; Barker RA
    CNS Drugs; 2006; 20(6):477-505. PubMed ID: 16734499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's Disease and its Related Dementia Types: A Review on Their Management
    Siafaka PI; Mutlu G; Okur NÜ
    Curr Alzheimer Res; 2020; 17(14):1239-1261. PubMed ID: 33602090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The understanding of Parkinson's disease through genetics and new therapies.
    Uwishema O; Onyeaka H; Badri R; Yücel AN; Korkusuz AK; Ajagbe AO; Abuleil A; Chaaya C; Alhendawi BHM; Chalhoub E
    Brain Behav; 2022 May; 12(5):e2577. PubMed ID: 35451243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pesticides and Parkinson's disease: Current and future perspective.
    Islam MS; Azim F; Saju H; Zargaran A; Shirzad M; Kamal M; Fatema K; Rehman S; Azad MAM; Ebrahimi-Barough S
    J Chem Neuroanat; 2021 Sep; 115():101966. PubMed ID: 33991619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.
    Si X; Pu J; Zhang B
    J Mov Disord; 2017 May; 10(2):69-79. PubMed ID: 28479587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational molecular imaging and drug development in Parkinson's disease.
    Haider A; Elghazawy NH; Dawoud A; Gebhard C; Wichmann T; Sippl W; Hoener M; Arenas E; Liang SH
    Mol Neurodegener; 2023 Feb; 18(1):11. PubMed ID: 36759912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of motor and non-motor symptoms in Parkinson's disease.
    Sprenger F; Poewe W
    CNS Drugs; 2013 Apr; 27(4):259-72. PubMed ID: 23515972
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.